News
Purple Biotech Ltd. ('Purple Biotech' or 'the Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing ...
Diakonos Oncology has dosed the first subject in its Phase II trial of investigational patient-derived double-loaded dendritic cell therapy, DOC1021, for treating a highly aggressive brain tumour, ...
The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback